A phase IIa study to evaluate the safety, pharmacodynamics and pharmacokinetics of TGN255 in stable haemodialysis patients

被引：0
|
作者：
Combe, Sophie
DSouza, Richard
Mysliwiec, Michal
Padmanabhan, Neal
Thomas, Mark
Villa, Giuseppe
Will, Eric
Patrick, Guy
Kennedy, Anthony
机构：
[1] Trigen, London, England
[2] Royal Devon & Exeter Hosp, Exeter Kidney Unit, Exeter EX2 5DW, Devon, England
[3] Bialystok Med Univ, Bialystok, Poland
[4] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland
[5] Birmingham Heartlands Hosp, Glaxo Renal Unit, Birmingham B9 5ST, W Midlands, England
[6] Fdn S Maugeri, Pavia, Italy
[7] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[8] Premier Res, Crowthorne, Berks, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 50 条
  • [1] Phase 1 interaction study between TGN255, a direct thrombin inhibitor, and aspirin plus clopidogrel
    Combe, S.
    Kennedy, A.
    Allen, G.
    EUROPEAN HEART JOURNAL, 2006, 27 : 762 - 762
  • [2] A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, Jean-Charles
    De Braud, Filippo G.
    Bahleda, Ratislav
    Adamo, Barbara
    Cereda, Roberta
    Camboni, Maria Gabriella
    Robert, Renate
    Isaacson, Jeffrey D.
    Litten, Jason B.
    Allen, Andrew R.
    Rolfe, Lindsey
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, J. -C.
    DeBraud, F.
    Bahleda, R.
    Adamo, B.
    Andre, F.
    Dientsmann, R.
    Delmonte, A.
    Cereda, R.
    Isaacson, J.
    Litten, J.
    Allen, A.
    Dubois, F.
    Saba, C.
    Robert, R.
    D'Incalci, M.
    Zucchetti, M.
    Camboni, M. G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2244 - 2251
  • [4] Phase I double blind, placebo controlled, ascending single intravenous dose study with a synthetic direct thrombin inhibitor, TGN255
    Combe, S
    Allen, G
    Kennedy, T
    PROCEEDINGS OF THE 18TH INTERNATIONAL CONGRESS ON THROMBOSIS, 2004, : 107 - 110
  • [5] A phase 1 double-blind 24-hour intravenous infusion study with TGN255, a direct thrombin inhibitor.
    Combe, S
    Allen, G
    Kennedy, T
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 195E - 195E
  • [6] A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161 in Chinese healthy volunteers
    Yap, D.
    Zhou, X.
    Chen, X.
    Lee, M.
    Zhang, Y.
    Wang, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1178 - 1179
  • [7] A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia
    Yin, Wei
    Han, David
    Khudyakov, Polyna
    Behrje, Rhett
    Posener, Joel
    Laurenza, Antonio
    Arkilo, Dimitrios
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3872 - 3882
  • [8] Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Adolescents: An Open-label Phase IIa Study
    Lobmeyer, Maximilian T.
    Lehr, Thorsten
    Halton, Jacqueline M.
    Cronin, Lisa
    Haertter, Sebastian
    Mitchell, Lesley
    CIRCULATION, 2014, 130
  • [9] Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease
    Li, Haiyan
    Guo, Jingchuan
    Carlson, Glenn F.
    Teng, Renli
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (02) : 352 - 361
  • [10] Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease
    Hiasa Y.
    Teng R.
    Emanuelsson H.
    Cardiovascular Intervention and Therapeutics, 2014, 29 (4) : 324 - 333
12345